Poseida Therapeutics (NASDAQ:PSTX) Earns “Neutral” Rating from BTIG Research

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “neutral” rating reiterated by equities researchers at BTIG Research in a note issued to investors on Tuesday,Benzinga reports.

A number of other brokerages have also weighed in on PSTX. William Blair reaffirmed a “market perform” rating on shares of Poseida Therapeutics in a report on Tuesday. HC Wainwright restated a “neutral” rating and set a $9.00 price objective (down from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $9.50.

Poseida Therapeutics Price Performance

Shares of PSTX opened at $9.33 on Tuesday. Poseida Therapeutics has a twelve month low of $1.87 and a twelve month high of $9.42. The stock’s 50 day moving average is $3.02 and its two-hundred day moving average is $3.01. The firm has a market capitalization of $909.35 million, a PE ratio of -14.81 and a beta of 0.54. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68.

Insider Buying and Selling at Poseida Therapeutics

In other news, Chairman Mark J. Gergen sold 30,000 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total transaction of $278,100.00. Following the completion of the sale, the chairman now directly owns 651,291 shares in the company, valued at $6,037,467.57. This represents a 4.40 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 2.90% of the stock is currently owned by insiders.

Institutional Trading of Poseida Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Poseida Therapeutics by 16.3% during the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after purchasing an additional 473,746 shares during the period. State Street Corp boosted its position in Poseida Therapeutics by 2.3% during the 3rd quarter. State Street Corp now owns 1,710,565 shares of the company’s stock worth $4,892,000 after purchasing an additional 38,770 shares during the period. Blair William & Co. IL boosted its position in Poseida Therapeutics by 14.1% during the 2nd quarter. Blair William & Co. IL now owns 1,101,325 shares of the company’s stock worth $3,216,000 after purchasing an additional 136,273 shares during the period. Renaissance Technologies LLC boosted its position in Poseida Therapeutics by 53.4% during the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after purchasing an additional 297,500 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its position in Poseida Therapeutics by 89.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 830,127 shares of the company’s stock worth $2,648,000 after purchasing an additional 391,801 shares during the period. 46.87% of the stock is currently owned by institutional investors and hedge funds.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.